Cancer Immunology Project (CIP), Universal Scientific Education & Research Network (USERN), Tehran, Iran.
Digestive Diseases Research Cores Center, Division of Gastroenterology, School of Medicine, Washington University, St. Louis, USA.
Immunotherapy. 2019 Mar;11(4):347-364. doi: 10.2217/imt-2018-0093.
Gastric cancer (GC) is the second leading cause of cancer-related death world-wide. Despite improvements in prevention, early detection and various therapeutic options, the prognosis is still poor. GC is often diagnosed at an advanced stage with survivals less than 1 year. Chemotherapy as the mainstay of treatment in advanced stage is not of notable advantages, underlining the need for novel more effective therapeutic options. Based on current knowledge of molecular and cellular mechanisms, a number of novel biologic approaches such as monoclonal antibodies have been recently introduced for cancer treatment that mainly affect the immune system or target signaling pathways playing role in cancer and metastasis development. In this review, various monoclonal antibodies for GC therapy were explained.
胃癌（GC）是全球癌症相关死亡的第二大主要原因。尽管在预防、早期检测和各种治疗选择方面有所改善，但预后仍然很差。GC 通常在晚期诊断，存活时间不到 1 年。化疗作为晚期治疗的主要手段并没有显著优势，这凸显了需要新型更有效的治疗选择。基于目前对分子和细胞机制的了解，最近已经引入了一些新型生物方法，如单克隆抗体，用于癌症治疗，这些方法主要影响免疫系统或针对在癌症和转移发展中起作用的信号通路。在这篇综述中，解释了用于 GC 治疗的各种单克隆抗体。
